# Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)

> **NCT00659594** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 500 (actual)

## Conditions studied

- Rhinitis, Allergic, Seasonal
- Hay Fever

## Interventions

- **DRUG:** Ciclesonide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00659594
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2005-02
- **Final completion:** 2005-09
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2016-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00659594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00659594, "Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00659594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*